查看購物車
  • Simplified Chinese
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1827424

銀屑病藥物市場按藥物類別、給藥途徑、患者嚴重程度、銀屑病類型、患者類型、配銷通路和治療環境分類 - 全球預測 2025-2032

Psoriasis Drugs Market by Drug Class, Route Of Administration, Patient Severity, Psoriasis Type, Patient Type, Distribution Channel, Treatment Setting - Global Forecast 2025-2032
出版日期: | 出版商: 360iResearch | 英文 182 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2032 年，牛皮癬藥物市場將成長至 276.3 億美元，複合年成長率為 12.41%。

主要市場統計數據
基準年2024年 108.3億美元
預計2025年 121.8億美元
預測年份：2032年 276.3億美元
複合年成長率（%） 12.41%

權威介紹，總結了當前的治療方法、系統性壓力以及影響牛皮癬藥物開發和商業化的戰略問題

銀屑病藥物領域已進入一個由快速的科學進步和不斷變化的商業性動態所定義的階段。生物目標和口服小分子藥物的進展正在擴大治療選擇，並提高了人們對療效提升、緩解持久性和患者便利性的期望。同時，付款人審查、供應鏈複雜性以及不斷變化的監管要求迫使製造商和醫療保健提供者調整其營運和商業性模式。因此，產業相關人員必須將臨床前景與實際考慮因素（例如生產擴充性、現實世界安全監測以及差異化的價值溝通）相協調。

本引言摘要了目前的治療方法、主要的臨床和商業性壓力以及公司、臨床醫生和付款人目前面臨的策略問題，為後續分析組裝。它概述了治療類別、給藥途徑、患者嚴重程度、銀屑病亞型、患者人口統計、通路和治療環境如何影響路徑和長期治療模式。透過將近期創新置於現實的實施約束條件下，本節旨在幫助讀者評估策略選擇、預測營運瓶頸，並確定能夠帶來持續臨床和商業性回報的投資優先順序。

變革性的臨床、監管和商業轉變正在匯聚，重新定義銀屑病治療的差異化治療方法、獲取途徑和價值展示

科學突破、監管變革以及患者對個人化治療的期望正在重塑銀屑病治療的模式。針對白細胞介素路徑的生物製藥和口服標靶抑制劑加速了治療方案的分化，鼓勵臨床醫生針對傳統療法難以覆蓋的患者亞群，考慮針對特異性機制的治療方案。同時，監管政策也日趨簡化，使得臨床整合速度更快，因為可靠的生物標記和真實世界證據推動了新藥核准策略和適應症擴展。

藥物經濟學因素日益凸顯，迫使製造商透過比較有效性、耐久性、患者報告結果等來證明其價值，而不僅依賴臨床療效終點。分銷和交付創新，例如專科藥房的擴張、家庭給藥途徑和數位化依從性支持，正在改變患者與其治療方法的互動方式。因此，商業性成功越來越依賴一種綜合方法，該方法將臨床差異化與長期效用的確鑿證據、以患者為中心的交付解決方案以及與付款人一致的價值提案相結合。這種轉型正在為整個治療生態系統創造機會和競爭壓力。

未來十年中期美國關稅變化對牛皮癬藥物供應鏈、籌資策略和商業性准入動態的累積影響

近期，美國推出或調整醫藥原料和成品關稅結構的政策，為全球銀屑病藥物供應鏈帶來了新的複雜性。針對活性藥物成分、生物製藥成分和輔助材料的關稅變化，可能會增加依賴國際採購的製造商的本地採購成本，促使其重新評估供應商組合和物流策略。為此，企業正在評估近岸外包、雙重採購和合約對沖等措施，以穩定原料供應並保障生產連續性。

除了直接的成本影響外，關稅還可能透過提高供應鏈韌性來影響產品上市時間和市場進入活動的順序。跨境臨床試驗供應物流可能需要額外的海關規劃和緊急庫存，以確保入組時間。同時，擁有垂直整合或國內生技藥品生產能力的製造商可能會在成本可預測性和監管合規性方面獲得策略優勢。重要的是，付款人和採購相關人員對持續的定價壓力非常敏感，這可能會影響處方集動態和合約談判，從而影響製造商在回扣、風險分擔協議和患者援助計劃方面的策略。

摘要：關稅將成為更廣泛的供應鏈現代化和製造業地理多元化的催化劑。因此，建議相關人員採取整體視角，在短期營運觀點與製造敏捷性、替代採購和合作安排方面的長期投資之間取得平衡，以減少貿易政策波動的影響。

全面的細分主導洞察，將策略重點與治療層級、給藥途徑、患者表現型、人口統計、分銷管道和醫療保健環境聯繫起來

深入了解銀屑病市場的詳細情形，有助於產品開發、臨床定位和商業性運作。生物製藥包括IL-17抑制劑、IL-23抑制劑和TNF抑制劑等標靶藥物，而小分子藥物則包括JAK抑制劑、PDE4抑制劑等。每類藥物的療效、安全性、劑量和生產流程均有差異，這些因素會影響臨床醫師的選擇和報銷談判。

給藥途徑是決定病患偏好和醫療保健系統工作流程的關鍵因素，涵蓋注射劑、口服劑和外用劑。注射劑進一步分為靜脈注射和皮下注射，每種注射劑都有其獨特的臨床監測和給藥基礎設施需求。口服劑包括膠囊、混懸液和錠劑，其給藥便利性和藥物動力學特徵各不相同。患者病情嚴重程度分為輕度至中度或中度至重度，決定了升級途徑以及全身性治療和生物製藥的適應症。

乾癬在臨床上表現為不同的亞型，包括紅皮病型、斑塊狀乾癬、逆性乾癬、指甲乾癬、斑塊狀乾癬、膿皰型乾癬和頭皮乾癬，這些表現型通常需要差異化的治療策略和療效指標。患者群體涵蓋成人、老年人和兒童，每種族群都有其獨特的安全性和劑量考量，這些因素會影響附加檔、研究設計和市場定位。分銷管道影響藥物的可及性和支持，包括醫院藥房、線上藥房、零售店和專科藥房，它們在報銷調整和病患教育方面發揮著各種作用。最後，治療環境涵蓋居家照護、醫院管理以及皮膚科專科診所，這些環境塑造了服務提供模式、依從性支援和遠端監控機會。這些細分領域必須整合到臨床開發計劃、上市策略和付款人參與框架中，以確保與現實世界的治療途徑和相關人員的需求保持一致。

美洲、歐洲、中東和非洲以及亞太地區的區域動態影響監管策略、取得途徑和商業化方法

美洲、歐洲、中東和非洲以及亞太地區的區域動態持續影響研發重點、監管計畫和商業策略。在美洲，成熟的法規環境和成熟的專業醫療網路有利於快速引入創新生技藥品和先進的支援服務，而付款人談判和處方集的投放仍然至關重要。在該地區，臨床醫生網路和患者支持管道通常支持高效療法的早期採用模式，而報銷機制則要求明確證明長期效益。

歐洲、中東和非洲的法律規範分散，支付系統多樣，因此需要製定區域性客製化的價值劑量和真實世界證據策略，以確保藥物的可及性。平行的監管路徑和對衛生技術評估的嚴格審查通常需要比較療效和成本效益的證據，這迫使製造商在多個國家/地區產生數據並製定差異化的定價策略。此外，某些市場的供應鏈限制會影響分銷選擇以及對本地夥伴關係策略的需求。

亞太市場呈現已開發都市區快速採用和新興市場准入不均衡的異質性組合。監管時間表和國內製造政策可能會影響上市定序，具有不同基因或表現型特徵的患者群體可能需要有針對性的臨床證據。在所有地區，專科藥房、數位互動工具和家庭護理解決方案日益重要的作用正在再形成患者病人歷程，要求製造商建立本地客製化的患者支援和商業模式。這些區域差異應指南上市資源、證據產生和經銷夥伴關係的優先排序。

企業級策略著重於銀屑病藥物的臨床差異化、製造敏捷性、支付方一致的證據生成以及以患者為中心的商業化

活躍於銀屑病藥物領域的大型製藥和生物技術公司需要應對各種複雜因素，例如臨床差異化、生產需求和付款人合作。成熟的生技藥品開發商正在加大對下一代白細胞介素標靶藥物及其生命週期管理的投資，而規模較小的生物技術公司則專注於創新的作用機制和生物標記主導的適應症。同時，專科製藥公司正在開發口服小分子藥物，重點關注給藥的便利性和聯合用藥策略，以滿足尋求注射以外治療方案的患者亞群的需求。在這些多元化的公司中，策略重點都集中在證明持續療效、提高安全性以及透過交付和支援方面的創新來最佳化患者體驗。

在營運方面，企業正在加強製造敏捷性，並與合約研究和受託製造廠商合作，以確保生技藥品的生產能力，並確保快速擴大臨床和商業供應規模。在商業方面，企業正在投資真實世界結果研究和長期安全監測，以使證據生成與付款人的期望保持一致。與專業藥房和數位醫療供應商的合作日益普遍，以支持依從性、遠端監控和病患教育。成熟的企業通常利用全球網路來加快監管提交和市場進入的速度，而新興參與企業則優先考慮利基差異化、策略夥伴關係和有針對性的臨床項目，以在特定患者群體中站穩腳跟。在這種競爭激烈的環境中，治療方法創新必須以強大的供應、證據和以病人為中心的商業化能力為支持。

產業領導者可採取的策略重點是協調臨床差異化、製造彈性、付款人參與度和以病人為中心的商業化，以獲得持久的成功

為了在不斷變化的銀屑病領域取得成功，行業領導者應採取多管齊下的策略，在科研投入、務實的商業營運和付款人參與之間取得平衡。優先考慮將清晰的機制差異化與強大的安全性和耐久性終點相結合的開發項目，並設計能夠記錄患者報告結果和真實世界療效的臨床試驗，以支持整體價值陳述。同時，投資於生產彈性，包括區域產能和可行的替代供應商，以減輕貿易政策波動帶來的風險，並確保臨床和商業供應的不間斷。

為了使證據產生與報銷預期相符，我們與付款方和醫療技術評估機構進行早期和反覆的合作，以建立創新的合約安排，共擔風險並證明療效的相關性。我們與專業藥房和數位醫療服務提供者建立夥伴關係，以增強依從性、遠端監控和家庭管理能力，並投資於分銷和患者支援生態系統。最後，我們實施在地化的上市方案，根據當地系統特點客製化監管提交、定價策略和病人參與，同時保持全球證據的一致性。透過將臨床卓越性與營運韌性以及以付款方為中心的價值證明相結合，組織可以建立一條通往持續應用和有意義的患者療效的可靠途徑。

支持報告策略和營運結論的調查方法的詳細資訊，包括對關鍵專家的調查、對次要證據的三角測量以及基於情景的分析

本研究整合了對一手資料和二手資料的結構化審查、專家諮詢和定性分析，以確保研究結果嚴謹可靠。主要資訊包括對臨床意見領袖、付款方、供應鏈專家和商業高管的訪談，以提供有關治療採用、報銷動態和營運限制的背景資訊。二手資料研究涵蓋同行評審的臨床文獻、監管指南文件、上市公司揭露資訊和生產技術文獻，以支持臨床機制、安全考量和生產現狀。

此分析方法結合了定性輸入的主題綜合、監管和臨床證據的交叉檢驗以及基於情境的供應鏈和政策影響評估。調查方法和資料來源強調資料來源的透明度、對不同資訊來源的仔細三角測量以及對營運風險因素的敏感度分析。為了盡可能減少偏見，研究結果由多個獨立資訊來源證實，並由專家評審員檢驗臨床解讀和策略影響。具體而言，該分析著重於結構、臨床和營運動態，而非定量市場預測。這種方法支持為策略規劃、產品開發優先排序和證據產生策略提供可行的見解。

對研究結果的全面回顧強調了整合科學創新、營運彈性、付款人一致的證據和以患者為中心的服務以實現治療效果的必要性。

總而言之，銀屑病藥物領域在提供科研機會的同時也增加了營運和商業性的複雜性。生物製藥和標靶小分子藥物的進展提高了治療標準，但要成功地將這些進展轉化為持續的患者獲益，需要製定一個綜合策略，將證據生成、生產韌性和以支付方為中心的價值展示融為一體。相關人員必須認知到，單靠臨床差異化是不夠的，還需要在供應鏈敏捷性、以患者為中心的交付機制以及能夠證明長期療效的真實世界證據項目方面進行同步投資。

展望未來，那些積極主動地將臨床開發與切實可行的可及性策略和強大的患者支持模式相結合的公司，將更有能力應對監管多樣性和付款人需求。此外，那些調整供應網路以降低政策和貿易風險的公司，將在產品上市執行和供應連續性方面獲得競爭優勢。最終，將科學創新與卓越營運和策略合作相結合的整體方法，將實現永續的商業性績效，同時推動患者照護的顯著改善。

目錄

第1章：前言

第2章調查方法

第3章執行摘要

第4章 市場概況

第5章 市場洞察

  • 白細胞介素抑制劑的日益普及正在改變中度至重度牛皮癬的治療模式
  • 生物相似藥替代品的出現促進了慢性牛皮癬治療中具有成本效益的選擇
  • JAK抑制劑安全性資料的重要性日益提升，再形成了處方醫師對新型乾癬治療的信心
  • 整合數位健康平台，提高病患依從性和乾癬遠端監測
  • 透過對牛皮癬患者的生物標記研究擴大個人化醫療努力
  • 增加遠距皮膚病學服務的可用性，並改善服務不足地區獲得牛皮癬治療的機會

第6章：2025年美國關稅的累積影響

第7章：人工智慧的累積影響，2025年

8. 銀屑病藥物市場（依藥物類別）

  • 生物製藥
    • IL-17抑制劑
    • IL-23抑制劑
    • TNF抑制劑
  • 小分子
    • JAK抑制劑
    • PDE4抑制劑

9. 牛皮癬藥物市場（依給藥途徑）

  • 注射
    • 靜脈
    • 皮下
  • 口服
    • 膠囊
    • 暫停
    • 藥片
  • 外用
    • 奶油
    • 形式
    • 凝膠
    • 軟膏

第 10 章 銀屑病藥物市場（依患者嚴重程度）

  • 輕度至中度
  • 中度至重度

第11章 銀屑病藥物市場（依銀屑病類型）

  • 紅皮病型乾癬
  • 水滴狀乾癬
  • 反向型乾癬
  • 指甲牛皮癬
  • 斑塊型乾癬
  • 膿皰型乾癬
  • 頭皮牛皮癬

第12章 銀屑病藥物市場（依患者類型）

  • 成人
  • 老年人
  • 孩子們

第13章 銀屑病藥物市場（依分銷管道）

  • 醫院藥房
  • 網路藥局
  • 零售藥局
  • 專業藥房

第14章 銀屑病藥物市場（依治療環境）

  • 家庭治療
  • 醫院護理
  • 專科皮膚科診所

第15章 銀屑病藥物市場（按地區）

  • 美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第16章 銀屑病藥物市場（依類別）

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第17章 銀屑病藥物市場（依國家）

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第18章競爭格局

  • 2024年市佔率分析
  • 2024年FPNV定位矩陣
  • 競爭分析
    • AbbVie Inc.
    • Johnson & Johnson
    • Novartis AG
    • Amgen Inc.
    • Eli Lilly and Company
    • Pfizer Inc.
    • UCB SA
    • Merck & Co., Inc.
    • Bristol-Myers Squibb Company
    • Sanofi SA
Product Code: MRR-434CCDA051B5

The Psoriasis Drugs Market is projected to grow by USD 27.63 billion at a CAGR of 12.41% by 2032.

KEY MARKET STATISTICS
Base Year [2024] USD 10.83 billion
Estimated Year [2025] USD 12.18 billion
Forecast Year [2032] USD 27.63 billion
CAGR (%) 12.41%

An authoritative introduction summarizing the current therapeutic modalities, systemic pressures, and strategic questions shaping psoriasis drug development and commercialization

The psoriasis therapeutics landscape has entered a phase defined by rapid scientific progress and shifting commercial dynamics. Advances in targeted biologic agents and oral small molecules have expanded therapeutic options and raised expectations for improved efficacy, remission durability, and patient convenience. At the same time, payer scrutiny, supply chain complexity, and evolving regulatory expectations require manufacturers and healthcare providers to adapt operational and commercial approaches. Consequently, industry stakeholders must reconcile clinical promise with pragmatic considerations including manufacturing scalability, real-world safety monitoring, and differentiated value communication.

This introduction frames the subsequent analysis by summarizing the current therapeutic modalities, the principal clinical and commercial pressures, and the strategic questions that companies, clinicians, and payers are now confronting. It outlines how therapeutic classification, administration route, patient severity, psoriasis subtype, patient demographics, distribution channels, and treatment settings collectively shape adoption pathways and long-term care models. By situating recent innovations within realistic implementation constraints, this section prepares readers to assess strategic options, anticipate operational bottlenecks, and prioritize investments that will deliver sustained clinical and commercial returns.

Transformative clinical, regulatory, and commercial shifts are converging to redefine therapeutic differentiation, access pathways, and value demonstration in psoriasis care

The psoriasis treatment paradigm is being reshaped by converging scientific breakthroughs, regulatory evolution, and patient expectations for personalized care. Biologics targeting interleukin pathways and orally administered targeted inhibitors have accelerated therapeutic differentiation, leading clinicians to consider mechanism-specific choices for patient subgroups previously underserved by older treatments. Concurrently, regulatory pathways are accommodating more streamlined approval strategies for novel agents and for label expansions based on robust biomarker and real-world evidence, enabling faster clinical integration.

Pharmacoeconomic considerations have gained prominence, compelling manufacturers to demonstrate value through comparative effectiveness, durability, and patient-reported outcomes rather than relying solely on clinical efficacy endpoints. Distribution and delivery innovations, including increased use of specialty pharmacies, home-based administration pathways, and digital adherence supports, are altering how patients engage with treatment regimens. As a result, commercial success increasingly depends on an integrated approach that aligns clinical differentiation with robust evidence of long-term benefit, patient-centric delivery solutions, and payer-aligned value propositions. These transformative shifts are creating both opportunities and heightened competitive pressures across the therapeutic ecosystem.

Cumulative implications of evolving United States tariff measures on psoriasis drug supply chains, sourcing strategies, and commercial access dynamics through mid-decade

Recent policy developments introducing or adjusting United States tariff structures for pharmaceutical inputs and finished products have introduced new layers of complexity into global psoriasis drug supply chains. Tariff changes targeting active pharmaceutical ingredients, biologic components, and ancillary materials have the potential to increase landed costs for manufacturers that rely on international sourcing, prompting reassessments of supplier portfolios and logistics strategies. In response, organizations are evaluating nearshoring, dual-sourcing, and contractual hedges to stabilize input availability and protect production continuity.

Beyond direct cost implications, tariffs can influence the timing of product launches and the sequencing of market access activities by shifting operational priorities toward supply-chain resilience. Clinical trial supply logistics that span borders may require additional customs planning and contingency stock to maintain enrollment schedules. Meanwhile, manufacturers with vertically integrated production or domestic biologics manufacturing capabilities may find strategic advantages in cost predictability and regulatory alignment. Importantly, payers and procurement stakeholders are sensitive to any sustained pricing pressures that could affect formulary dynamics and contracting negotiations, which in turn influences manufacturer strategies for rebates, risk-sharing agreements, and patient support programs.

In summary, tariffs act as a catalyst for broader supply-chain modernization and geographic diversification of manufacturing. Stakeholders are therefore advised to adopt a holistic view that balances near-term operational responses with longer-term investments in manufacturing agility, alternative sourcing, and collaborative agreements that mitigate exposure to trade policy volatility.

Comprehensive segmentation-driven insights linking therapeutic class, administration route, patient phenotype, demographics, distribution channels, and care settings to strategic priorities

A nuanced understanding of how the psoriasis market segments informs product development, clinical positioning, and commercial engagement. Therapeutic classification differentiates between biologic therapies and small-molecule agents; biologics encompass targeted classes such as IL-17 inhibitors, IL-23 inhibitors, and TNF inhibitors, while small molecules include JAK inhibitors and PDE4 inhibitors. Each class carries distinct efficacy, safety, administration, and manufacturing considerations that influence clinician selection and reimbursement discussions.

Route of administration is a critical determinant of patient preference and health-system workflows, spanning injectable, oral, and topical modalities. Injectable formulations are further categorized by intravenous and subcutaneous delivery, each with unique clinical monitoring and administration infrastructure requirements; oral options include capsules, suspensions, and tablets that vary in dosing convenience and pharmacokinetic profiles; topical therapies are formulated as creams, foams, gels, or ointments tailored to lesion characteristics and patient adherence. Patient severity divides the landscape into mild-to-moderate and moderate-to-severe presentations, guiding escalation pathways and eligibility for systemic or biologic therapies.

Psoriasis manifests in clinically distinct subtypes including erythrodermic, guttate, inverse, nail, plaque, pustular, and scalp presentations, and these phenotypes often necessitate differentiated therapeutic strategies and outcome metrics. Patient demographics span adults, geriatric populations, and pediatric cohorts, each with unique safety and dosing considerations that affect labeling, trial design, and market positioning. Distribution channels influence access and support structures, encompassing hospital pharmacies, online pharmacies, retail outlets, and specialty pharmacies that play varying roles in reimbursement coordination and patient education. Finally, treatment settings range from home-based care to hospital-based management and specialty dermatology clinics, shaping service delivery models, adherence supports, and opportunities for remote monitoring. Collectively, these segmentation dimensions should be integrated into clinical development plans, commercial launch strategies, and payer engagement frameworks to ensure alignment with real-world treatment pathways and stakeholder needs.

Region-specific dynamics across the Americas, Europe Middle East & Africa, and Asia-Pacific that influence regulatory strategy, access pathways, and commercialization approaches

Regional dynamics continue to shape development priorities, regulatory planning, and commercial strategies across the Americas, Europe, Middle East & Africa, and Asia-Pacific. In the Americas, a mature regulatory environment and established specialty care networks favor rapid uptake of innovative biologics and advanced support services, alongside ongoing emphasis on payer negotiations and formulary placement. Clinician networks and patient advocacy channels in this region frequently drive early adoption patterns for high-efficacy therapies, while reimbursement mechanisms require clear demonstration of long-term benefit.

In Europe, Middle East & Africa, fragmented regulatory frameworks and diverse payer systems necessitate regionally tailored value dossiers and real-world evidence strategies to secure access. Parallel regulatory pathways and heightened health-technology assessment scrutiny often demand comparative effectiveness and cost-effectiveness evidence, prompting manufacturers to plan multi-country data generation and differentiated pricing strategies. In addition, supply-chain constraints in some markets influence distribution choices and the need for local partnership strategies.

Asia-Pacific markets display a heterogeneous mix of rapid adoption in advanced urban centers and variable access across emerging markets. Regulatory timelines and domestic manufacturing policies can influence launch sequencing, and patient populations with distinct genetic or phenotypic characteristics may require targeted clinical evidence. Across all regions, the increasing role of specialty pharmacies, digital engagement tools, and home-based treatment solutions is reshaping patient journeys and requiring manufacturers to craft region-sensitive patient support and commercial models. These regional nuances should guide prioritization of launch resources, evidence generation, and distribution partnerships.

Company-level strategies emphasizing clinical differentiation, manufacturing agility, payer-aligned evidence generation, and patient-centric commercialization in psoriasis therapeutics

Leading pharmaceutical and biotech companies active in psoriasis therapeutics are navigating a complex mix of clinical differentiation, manufacturing demands, and payer engagement. Established biologics developers are intensifying investments in next-generation interleukin-targeting agents and lifecycle management, while smaller biotechs focus on innovative mechanisms of action and biomarker-driven indications. Concurrently, specialty pharmaceutical firms are advancing oral small molecules that emphasize ease of administration and combination strategies to address patient subgroups seeking non-injectable options. Across these varied company profiles, strategic priorities coalesce around demonstrating durable efficacy, improving safety profiles, and optimizing patient experience through delivery and support innovations.

Operationally, companies are strengthening manufacturing agility and partnering with contract development and manufacturing organizations to secure biologics capacity and ensure rapid scale-up for clinical and commercial supply. Commercially, organizations are aligning evidence generation with payer expectations by investing in real-world outcomes research and longitudinal safety monitoring. Collaboration with specialty pharmacies and digital health vendors is increasingly common to support adherence, remote monitoring, and patient education. Mature players often leverage global networks to expedite regulatory filings and market entry, while emerging entrants prioritize niche differentiation, strategic partnerships, and targeted clinical programs to gain footholds in specific patient segments. The combined effect is a competitive environment where therapeutic innovation must be matched by robust supply, evidence, and patient-centric commercialization capabilities.

Actionable strategic priorities for industry leaders to align clinical differentiation, manufacturing resilience, payer engagement, and patient-centric commercialization for durable success

Industry leaders should adopt a multi-pronged strategy that balances scientific investment with pragmatic operations and payer engagement to prosper in the evolving psoriasis landscape. Prioritize development programs that pair clear mechanistic differentiation with robust safety and durability endpoints, and design clinical trials that capture patient-reported outcomes and real-world effectiveness dimensions to support comprehensive value narratives. Simultaneously, commit resources to manufacturing flexibility, including regional capacity and validated alternate suppliers, to reduce exposure to trade policy fluctuations and to support uninterrupted clinical and commercial supply.

Engage early and iteratively with payers and health-technology assessment bodies to align evidence generation with reimbursement expectations, and structure innovative contracting arrangements that share risk and demonstrate outcome linkage. Invest in distribution and patient-support ecosystems by cultivating partnerships with specialty pharmacies and digital health providers that enhance adherence, remote monitoring, and home-based administration capabilities. Finally, implement a regionalized market-entry playbook that tailors regulatory submissions, pricing strategies, and patient engagement to local system characteristics while preserving global evidence coherence. By integrating clinical excellence with operational resilience and payer-centric value demonstration, organizations can create defensible pathways to sustained adoption and meaningful patient outcomes.

Methodology detailing primary expert engagements, secondary evidence triangulation, and scenario-based analyses underpinning strategic and operational conclusions in the report

This research synthesizes a structured review of primary and secondary sources, expert consultations, and qualitative analyses to ensure rigorous and defensible findings. Primary inputs included interviews with clinical thought leaders, payers, supply-chain specialists, and commercial executives who provided context on treatment adoption, reimbursement dynamics, and operational constraints. Secondary research encompassed peer-reviewed clinical literature, regulatory guidance documents, public company disclosures, and technical manufacturing references to corroborate clinical mechanisms, safety considerations, and production realities.

Analytical methods integrated thematic synthesis of qualitative inputs, cross-validation of regulatory and clinical evidence, and scenario-based assessment of supply-chain and policy impacts. The methodology emphasized transparency in data provenance, careful triangulation of diverse information sources, and sensitivity analyses for operational risk factors. Where possible, findings were corroborated with multiple independent sources to reduce bias, and expert reviewers provided validation of clinical interpretations and strategic implications. Limitations are acknowledged; specifically, the analysis focuses on structural, clinical, and operational dynamics rather than quantitative market projections. The approach supports actionable insights for strategic planning, product development prioritization, and evidence generation strategies.

Concluding synthesis highlighting the imperative to integrate scientific innovation, operational resilience, payer-aligned evidence, and patient-centric delivery to realize therapeutic impact

In conclusion, the psoriasis therapeutics landscape offers substantial scientific opportunity coupled with heightened operational and commercial complexity. Advances in biologics and targeted small molecules have raised the standard of care, yet successful translation into sustained patient benefit requires comprehensive strategies that integrate evidence generation, manufacturing resilience, and payer-aligned value demonstration. Stakeholders must recognize that clinical differentiation alone is insufficient without parallel investments in supply-chain agility, patient-centric delivery mechanisms, and real-world evidence programs that substantiate long-term outcomes.

Moving forward, companies that proactively align clinical development with pragmatic access strategies and robust patient support models will be best positioned to navigate regulatory heterogeneity and payer demands. Moreover, organizations that adapt supply networks to mitigate policy and trade risks can secure competitive advantages in launch execution and continuity of supply. Ultimately, a holistic approach that marries scientific innovation with operational excellence and strategic collaborations will drive meaningful improvements in patient care while enabling sustainable commercial performance.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Rising adoption of interleukin inhibitors transforming moderate to severe psoriasis treatment landscapes
  • 5.2. Emergence of biosimilar alternatives driving cost-effective options for chronic psoriasis management
  • 5.3. Growing emphasis on JAK inhibitor safety data reshaping prescriber confidence in new psoriasis therapies
  • 5.4. Integration of digital health platforms enhancing patient adherence and remote monitoring for psoriasis
  • 5.5. Expansion of personalized medicine initiatives driven by biomarker research in psoriatic patients
  • 5.6. Increasing availability of teledermatology services improving access to psoriasis care in underserved regions

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Psoriasis Drugs Market, by Drug Class

  • 8.1. Biologics
    • 8.1.1. IL 17 Inhibitors
    • 8.1.2. IL 23 Inhibitors
    • 8.1.3. TNF Inhibitors
  • 8.2. Small Molecules
    • 8.2.1. JAK Inhibitors
    • 8.2.2. PDE4 Inhibitors

9. Psoriasis Drugs Market, by Route Of Administration

  • 9.1. Injectable
    • 9.1.1. Intravenous
    • 9.1.2. Subcutaneous
  • 9.2. Oral
    • 9.2.1. Capsules
    • 9.2.2. Suspensions
    • 9.2.3. Tablets
  • 9.3. Topical
    • 9.3.1. Creams
    • 9.3.2. Foams
    • 9.3.3. Gels
    • 9.3.4. Ointments

10. Psoriasis Drugs Market, by Patient Severity

  • 10.1. Mild To Moderate
  • 10.2. Moderate To Severe

11. Psoriasis Drugs Market, by Psoriasis Type

  • 11.1. Erythrodermic Psoriasis
  • 11.2. Guttate Psoriasis
  • 11.3. Inverse Psoriasis
  • 11.4. Nail Psoriasis
  • 11.5. Plaque Psoriasis
  • 11.6. Pustular Psoriasis
  • 11.7. Scalp Psoriasis

12. Psoriasis Drugs Market, by Patient Type

  • 12.1. Adults
  • 12.2. Geriatric
  • 12.3. Pediatric

13. Psoriasis Drugs Market, by Distribution Channel

  • 13.1. Hospital Pharmacies
  • 13.2. Online Pharmacies
  • 13.3. Retail Pharmacies
  • 13.4. Specialty Pharmacies

14. Psoriasis Drugs Market, by Treatment Setting

  • 14.1. Home-Based Treatment
  • 14.2. Hospital-Based Care
  • 14.3. Specialty Dermatology Clinics

15. Psoriasis Drugs Market, by Region

  • 15.1. Americas
    • 15.1.1. North America
    • 15.1.2. Latin America
  • 15.2. Europe, Middle East & Africa
    • 15.2.1. Europe
    • 15.2.2. Middle East
    • 15.2.3. Africa
  • 15.3. Asia-Pacific

16. Psoriasis Drugs Market, by Group

  • 16.1. ASEAN
  • 16.2. GCC
  • 16.3. European Union
  • 16.4. BRICS
  • 16.5. G7
  • 16.6. NATO

17. Psoriasis Drugs Market, by Country

  • 17.1. United States
  • 17.2. Canada
  • 17.3. Mexico
  • 17.4. Brazil
  • 17.5. United Kingdom
  • 17.6. Germany
  • 17.7. France
  • 17.8. Russia
  • 17.9. Italy
  • 17.10. Spain
  • 17.11. China
  • 17.12. India
  • 17.13. Japan
  • 17.14. Australia
  • 17.15. South Korea

18. Competitive Landscape

  • 18.1. Market Share Analysis, 2024
  • 18.2. FPNV Positioning Matrix, 2024
  • 18.3. Competitive Analysis
    • 18.3.1. AbbVie Inc.
    • 18.3.2. Johnson & Johnson
    • 18.3.3. Novartis AG
    • 18.3.4. Amgen Inc.
    • 18.3.5. Eli Lilly and Company
    • 18.3.6. Pfizer Inc.
    • 18.3.7. UCB S.A.
    • 18.3.8. Merck & Co., Inc.
    • 18.3.9. Bristol-Myers Squibb Company
    • 18.3.10. Sanofi S.A.

LIST OF FIGURES

  • FIGURE 1. GLOBAL PSORIASIS DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL PSORIASIS DRUGS MARKET SIZE, BY DRUG CLASS, 2024 VS 2032 (%)
  • FIGURE 3. GLOBAL PSORIASIS DRUGS MARKET SIZE, BY DRUG CLASS, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 4. GLOBAL PSORIASIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2032 (%)
  • FIGURE 5. GLOBAL PSORIASIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL PSORIASIS DRUGS MARKET SIZE, BY PATIENT SEVERITY, 2024 VS 2032 (%)
  • FIGURE 7. GLOBAL PSORIASIS DRUGS MARKET SIZE, BY PATIENT SEVERITY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL PSORIASIS DRUGS MARKET SIZE, BY PSORIASIS TYPE, 2024 VS 2032 (%)
  • FIGURE 9. GLOBAL PSORIASIS DRUGS MARKET SIZE, BY PSORIASIS TYPE, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL PSORIASIS DRUGS MARKET SIZE, BY PATIENT TYPE, 2024 VS 2032 (%)
  • FIGURE 11. GLOBAL PSORIASIS DRUGS MARKET SIZE, BY PATIENT TYPE, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL PSORIASIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2032 (%)
  • FIGURE 13. GLOBAL PSORIASIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 14. GLOBAL PSORIASIS DRUGS MARKET SIZE, BY TREATMENT SETTING, 2024 VS 2032 (%)
  • FIGURE 15. GLOBAL PSORIASIS DRUGS MARKET SIZE, BY TREATMENT SETTING, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 16. GLOBAL PSORIASIS DRUGS MARKET SIZE, BY REGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 17. AMERICAS PSORIASIS DRUGS MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 18. NORTH AMERICA PSORIASIS DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 19. LATIN AMERICA PSORIASIS DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 20. EUROPE, MIDDLE EAST & AFRICA PSORIASIS DRUGS MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 21. EUROPE PSORIASIS DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 22. MIDDLE EAST PSORIASIS DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 23. AFRICA PSORIASIS DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 24. ASIA-PACIFIC PSORIASIS DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 25. GLOBAL PSORIASIS DRUGS MARKET SIZE, BY GROUP, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 26. ASEAN PSORIASIS DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 27. GCC PSORIASIS DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 28. EUROPEAN UNION PSORIASIS DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 29. BRICS PSORIASIS DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 30. G7 PSORIASIS DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 31. NATO PSORIASIS DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 32. GLOBAL PSORIASIS DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 33. PSORIASIS DRUGS MARKET SHARE, BY KEY PLAYER, 2024
  • FIGURE 34. PSORIASIS DRUGS MARKET, FPNV POSITIONING MATRIX, 2024

LIST OF TABLES

  • TABLE 1. PSORIASIS DRUGS MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
  • TABLE 3. GLOBAL PSORIASIS DRUGS MARKET SIZE, 2018-2024 (USD MILLION)
  • TABLE 4. GLOBAL PSORIASIS DRUGS MARKET SIZE, 2025-2032 (USD MILLION)
  • TABLE 5. GLOBAL PSORIASIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
  • TABLE 6. GLOBAL PSORIASIS DRUGS MARKET SIZE, BY DRUG CLASS, 2025-2032 (USD MILLION)
  • TABLE 7. GLOBAL PSORIASIS DRUGS MARKET SIZE, BY BIOLOGICS, 2018-2024 (USD MILLION)
  • TABLE 8. GLOBAL PSORIASIS DRUGS MARKET SIZE, BY BIOLOGICS, 2025-2032 (USD MILLION)
  • TABLE 9. GLOBAL PSORIASIS DRUGS MARKET SIZE, BY BIOLOGICS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 10. GLOBAL PSORIASIS DRUGS MARKET SIZE, BY BIOLOGICS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 11. GLOBAL PSORIASIS DRUGS MARKET SIZE, BY BIOLOGICS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 12. GLOBAL PSORIASIS DRUGS MARKET SIZE, BY BIOLOGICS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 13. GLOBAL PSORIASIS DRUGS MARKET SIZE, BY BIOLOGICS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 14. GLOBAL PSORIASIS DRUGS MARKET SIZE, BY BIOLOGICS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 15. GLOBAL PSORIASIS DRUGS MARKET SIZE, BY IL 17 INHIBITORS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 16. GLOBAL PSORIASIS DRUGS MARKET SIZE, BY IL 17 INHIBITORS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 17. GLOBAL PSORIASIS DRUGS MARKET SIZE, BY IL 17 INHIBITORS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 18. GLOBAL PSORIASIS DRUGS MARKET SIZE, BY IL 17 INHIBITORS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 19. GLOBAL PSORIASIS DRUGS MARKET SIZE, BY IL 17 INHIBITORS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 20. GLOBAL PSORIASIS DRUGS MARKET SIZE, BY IL 17 INHIBITORS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 21. GLOBAL PSORIASIS DRUGS MARKET SIZE, BY IL 23 INHIBITORS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 22. GLOBAL PSORIASIS DRUGS MARKET SIZE, BY IL 23 INHIBITORS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 23. GLOBAL PSORIASIS DRUGS MARKET SIZE, BY IL 23 INHIBITORS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 24. GLOBAL PSORIASIS DRUGS MARKET SIZE, BY IL 23 INHIBITORS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 25. GLOBAL PSORIASIS DRUGS MARKET SIZE, BY IL 23 INHIBITORS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 26. GLOBAL PSORIASIS DRUGS MARKET SIZE, BY IL 23 INHIBITORS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 27. GLOBAL PSORIASIS DRUGS MARKET SIZE, BY TNF INHIBITORS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 28. GLOBAL PSORIASIS DRUGS MARKET SIZE, BY TNF INHIBITORS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 29. GLOBAL PSORIASIS DRUGS MARKET SIZE, BY TNF INHIBITORS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 30. GLOBAL PSORIASIS DRUGS MARKET SIZE, BY TNF INHIBITORS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 31. GLOBAL PSORIASIS DRUGS MARKET SIZE, BY TNF INHIBITORS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 32. GLOBAL PSORIASIS DRUGS MARKET SIZE, BY TNF INHIBITORS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 33. GLOBAL PSORIASIS DRUGS MARKET SIZE, BY SMALL MOLECULES, 2018-2024 (USD MILLION)
  • TABLE 34. GLOBAL PSORIASIS DRUGS MARKET SIZE, BY SMALL MOLECULES, 2025-2032 (USD MILLION)
  • TABLE 35. GLOBAL PSORIASIS DRUGS MARKET SIZE, BY SMALL MOLECULES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 36. GLOBAL PSORIASIS DRUGS MARKET SIZE, BY SMALL MOLECULES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 37. GLOBAL PSORIASIS DRUGS MARKET SIZE, BY SMALL MOLECULES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 38. GLOBAL PSORIASIS DRUGS MARKET SIZE, BY SMALL MOLECULES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 39. GLOBAL PSORIASIS DRUGS MARKET SIZE, BY SMALL MOLECULES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 40. GLOBAL PSORIASIS DRUGS MARKET SIZE, BY SMALL MOLECULES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 41. GLOBAL PSORIASIS DRUGS MARKET SIZE, BY JAK INHIBITORS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 42. GLOBAL PSORIASIS DRUGS MARKET SIZE, BY JAK INHIBITORS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 43. GLOBAL PSORIASIS DRUGS MARKET SIZE, BY JAK INHIBITORS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 44. GLOBAL PSORIASIS DRUGS MARKET SIZE, BY JAK INHIBITORS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 45. GLOBAL PSORIASIS DRUGS MARKET SIZE, BY JAK INHIBITORS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 46. GLOBAL PSORIASIS DRUGS MARKET SIZE, BY JAK INHIBITORS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 47. GLOBAL PSORIASIS DRUGS MARKET SIZE, BY PDE4 INHIBITORS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 48. GLOBAL PSORIASIS DRUGS MARKET SIZE, BY PDE4 INHIBITORS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 49. GLOBAL PSORIASIS DRUGS MARKET SIZE, BY PDE4 INHIBITORS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 50. GLOBAL PSORIASIS DRUGS MARKET SIZE, BY PDE4 INHIBITORS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 51. GLOBAL PSORIASIS DRUGS MARKET SIZE, BY PDE4 INHIBITORS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 52. GLOBAL PSORIASIS DRUGS MARKET SIZE, BY PDE4 INHIBITORS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 53. GLOBAL PSORIASIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 54. GLOBAL PSORIASIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 55. GLOBAL PSORIASIS DRUGS MARKET SIZE, BY INJECTABLE, 2018-2024 (USD MILLION)
  • TABLE 56. GLOBAL PSORIASIS DRUGS MARKET SIZE, BY INJECTABLE, 2025-2032 (USD MILLION)
  • TABLE 57. GLOBAL PSORIASIS DRUGS MARKET SIZE, BY INJECTABLE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 58. GLOBAL PSORIASIS DRUGS MARKET SIZE, BY INJECTABLE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 59. GLOBAL PSORIASIS DRUGS MARKET SIZE, BY INJECTABLE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 60. GLOBAL PSORIASIS DRUGS MARKET SIZE, BY INJECTABLE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 61. GLOBAL PSORIASIS DRUGS MARKET SIZE, BY INJECTABLE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 62. GLOBAL PSORIASIS DRUGS MARKET SIZE, BY INJECTABLE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 63. GLOBAL PSORIASIS DRUGS MARKET SIZE, BY INTRAVENOUS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 64. GLOBAL PSORIASIS DRUGS MARKET SIZE, BY INTRAVENOUS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 65. GLOBAL PSORIASIS DRUGS MARKET SIZE, BY INTRAVENOUS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 66. GLOBAL PSORIASIS DRUGS MARKET SIZE, BY INTRAVENOUS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 67. GLOBAL PSORIASIS DRUGS MARKET SIZE, BY INTRAVENOUS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 68. GLOBAL PSORIASIS DRUGS MARKET SIZE, BY INTRAVENOUS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 69. GLOBAL PSORIASIS DRUGS MARKET SIZE, BY SUBCUTANEOUS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 70. GLOBAL PSORIASIS DRUGS MARKET SIZE, BY SUBCUTANEOUS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 71. GLOBAL PSORIASIS DRUGS MARKET SIZE, BY SUBCUTANEOUS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 72. GLOBAL PSORIASIS DRUGS MARKET SIZE, BY SUBCUTANEOUS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 73. GLOBAL PSORIASIS DRUGS MARKET SIZE, BY SUBCUTANEOUS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 74. GLOBAL PSORIASIS DRUGS MARKET SIZE, BY SUBCUTANEOUS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 75. GLOBAL PSORIASIS DRUGS MARKET SIZE, BY ORAL, 2018-2024 (USD MILLION)
  • TABLE 76. GLOBAL PSORIASIS DRUGS MARKET SIZE, BY ORAL, 2025-2032 (USD MILLION)
  • TABLE 77. GLOBAL PSORIASIS DRUGS MARKET SIZE, BY ORAL, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 78. GLOBAL PSORIASIS DRUGS MARKET SIZE, BY ORAL, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 79. GLOBAL PSORIASIS DRUGS MARKET SIZE, BY ORAL, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 80. GLOBAL PSORIASIS DRUGS MARKET SIZE, BY ORAL, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 81. GLOBAL PSORIASIS DRUGS MARKET SIZE, BY ORAL, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 82. GLOBAL PSORIASIS DRUGS MARKET SIZE, BY ORAL, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 83. GLOBAL PSORIASIS DRUGS MARKET SIZE, BY CAPSULES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 84. GLOBAL PSORIASIS DRUGS MARKET SIZE, BY CAPSULES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 85. GLOBAL PSORIASIS DRUGS MARKET SIZE, BY CAPSULES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 86. GLOBAL PSORIASIS DRUGS MARKET SIZE, BY CAPSULES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 87. GLOBAL PSORIASIS DRUGS MARKET SIZE, BY CAPSULES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 88. GLOBAL PSORIASIS DRUGS MARKET SIZE, BY CAPSULES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 89. GLOBAL PSORIASIS DRUGS MARKET SIZE, BY SUSPENSIONS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 90. GLOBAL PSORIASIS DRUGS MARKET SIZE, BY SUSPENSIONS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 91. GLOBAL PSORIASIS DRUGS MARKET SIZE, BY SUSPENSIONS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 92. GLOBAL PSORIASIS DRUGS MARKET SIZE, BY SUSPENSIONS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 93. GLOBAL PSORIASIS DRUGS MARKET SIZE, BY SUSPENSIONS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 94. GLOBAL PSORIASIS DRUGS MARKET SIZE, BY SUSPENSIONS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 95. GLOBAL PSORIASIS DRUGS MARKET SIZE, BY TABLETS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 96. GLOBAL PSORIASIS DRUGS MARKET SIZE, BY TABLETS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 97. GLOBAL PSORIASIS DRUGS MARKET SIZE, BY TABLETS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 98. GLOBAL PSORIASIS DRUGS MARKET SIZE, BY TABLETS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 99. GLOBAL PSORIASIS DRUGS MARKET SIZE, BY TABLETS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 100. GLOBAL PSORIASIS DRUGS MARKET SIZE, BY TABLETS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 101. GLOBAL PSORIASIS DRUGS MARKET SIZE, BY TOPICAL, 2018-2024 (USD MILLION)
  • TABLE 102. GLOBAL PSORIASIS DRUGS MARKET SIZE, BY TOPICAL, 2025-2032 (USD MILLION)
  • TABLE 103. GLOBAL PSORIASIS DRUGS MARKET SIZE, BY TOPICAL, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 104. GLOBAL PSORIASIS DRUGS MARKET SIZE, BY TOPICAL, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 105. GLOBAL PSORIASIS DRUGS MARKET SIZE, BY TOPICAL, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 106. GLOBAL PSORIASIS DRUGS MARKET SIZE, BY TOPICAL, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 107. GLOBAL PSORIASIS DRUGS MARKET SIZE, BY TOPICAL, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 108. GLOBAL PSORIASIS DRUGS MARKET SIZE, BY TOPICAL, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 109. GLOBAL PSORIASIS DRUGS MARKET SIZE, BY CREAMS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 110. GLOBAL PSORIASIS DRUGS MARKET SIZE, BY CREAMS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 111. GLOBAL PSORIASIS DRUGS MARKET SIZE, BY CREAMS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 112. GLOBAL PSORIASIS DRUGS MARKET SIZE, BY CREAMS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 113. GLOBAL PSORIASIS DRUGS MARKET SIZE, BY CREAMS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 114. GLOBAL PSORIASIS DRUGS MARKET SIZE, BY CREAMS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 115. GLOBAL PSORIASIS DRUGS MARKET SIZE, BY FOAMS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 116. GLOBAL PSORIASIS DRUGS MARKET SIZE, BY FOAMS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 117. GLOBAL PSORIASIS DRUGS MARKET SIZE, BY FOAMS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 118. GLOBAL PSORIASIS DRUGS MARKET SIZE, BY FOAMS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 119. GLOBAL PSORIASIS DRUGS MARKET SIZE, BY FOAMS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 120. GLOBAL PSORIASIS DRUGS MARKET SIZE, BY FOAMS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 121. GLOBAL PSORIASIS DRUGS MARKET SIZE, BY GELS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 122. GLOBAL PSORIASIS DRUGS MARKET SIZE, BY GELS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 123. GLOBAL PSORIASIS DRUGS MARKET SIZE, BY GELS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 124. GLOBAL PSORIASIS DRUGS MARKET SIZE, BY GELS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 125. GLOBAL PSORIASIS DRUGS MARKET SIZE, BY GELS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 126. GLOBAL PSORIASIS DRUGS MARKET SIZE, BY GELS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 127. GLOBAL PSORIASIS DRUGS MARKET SIZE, BY OINTMENTS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 128. GLOBAL PSORIASIS DRUGS MARKET SIZE, BY OINTMENTS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 129. GLOBAL PSORIASIS DRUGS MARKET SIZE, BY OINTMENTS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 130. GLOBAL PSORIASIS DRUGS MARKET SIZE, BY OINTMENTS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 131. GLOBAL PSORIASIS DRUGS MARKET SIZE, BY OINTMENTS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 132. GLOBAL PSORIASIS DRUGS MARKET SIZE, BY OINTMENTS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 133. GLOBAL PSORIASIS DRUGS MARKET SIZE, BY PATIENT SEVERITY, 2018-2024 (USD MILLION)
  • TABLE 134. GLOBAL PSORIASIS DRUGS MARKET SIZE, BY PATIENT SEVERITY, 2025-2032 (USD MILLION)
  • TABLE 135. GLOBAL PSORIASIS DRUGS MARKET SIZE, BY MILD TO MODERATE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 136. GLOBAL PSORIASIS DRUGS MARKET SIZE, BY MILD TO MODERATE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 137. GLOBAL PSORIASIS DRUGS MARKET SIZE, BY MILD TO MODERATE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 138. GLOBAL PSORIASIS DRUGS MARKET SIZE, BY MILD TO MODERATE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 139. GLOBAL PSORIASIS DRUGS MARKET SIZE, BY MILD TO MODERATE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 140. GLOBAL PSORIASIS DRUGS MARKET SIZE, BY MILD TO MODERATE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 141. GLOBAL PSORIASIS DRUGS MARKET SIZE, BY MODERATE TO SEVERE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 142. GLOBAL PSORIASIS DRUGS MARKET SIZE, BY MODERATE TO SEVERE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 143. GLOBAL PSORIASIS DRUGS MARKET SIZE, BY MODERATE TO SEVERE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 144. GLOBAL PSORIASIS DRUGS MARKET SIZE, BY MODERATE TO SEVERE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 145. GLOBAL PSORIASIS DRUGS MARKET SIZE, BY MODERATE TO SEVERE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 146. GLOBAL PSORIASIS DRUGS MARKET SIZE, BY MODERATE TO SEVERE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 147. GLOBAL PSORIASIS DRUGS MARKET SIZE, BY PSORIASIS TYPE, 2018-2024 (USD MILLION)
  • TABLE 148. GLOBAL PSORIASIS DRUGS MARKET SIZE, BY PSORIASIS TYPE, 2025-2032 (USD MILLION)
  • TABLE 149. GLOBAL PSORIASIS DRUGS MARKET SIZE, BY ERYTHRODERMIC PSORIASIS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 150. GLOBAL PSORIASIS DRUGS MARKET SIZE, BY ERYTHRODERMIC PSORIASIS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 151. GLOBAL PSORIASIS DRUGS MARKET SIZE, BY ERYTHRODERMIC PSORIASIS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 152. GLOBAL PSORIASIS DRUGS MARKET SIZE, BY ERYTHRODERMIC PSORIASIS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 153. GLOBAL PSORIASIS DRUGS MARKET SIZE, BY ERYTHRODERMIC PSORIASIS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 154. GLOBAL PSORIASIS DRUGS MARKET SIZE, BY ERYTHRODERMIC PSORIASIS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 155. GLOBAL PSORIASIS DRUGS MARKET SIZE, BY GUTTATE PSORIASIS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 156. GLOBAL PSORIASIS DRUGS MARKET SIZE, BY GUTTATE PSORIASIS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 157. GLOBAL PSORIASIS DRUGS MARKET SIZE, BY GUTTATE PSORIASIS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 158. GLOBAL PSORIASIS DRUGS MARKET SIZE, BY GUTTATE PSORIASIS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 159. GLOBAL PSORIASIS DRUGS MARKET SIZE, BY GUTTATE PSORIASIS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 160. GLOBAL PSORIASIS DRUGS MARKET SIZE, BY GUTTATE PSORIASIS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 161. GLOBAL PSORIASIS DRUGS MARKET SIZE, BY INVERSE PSORIASIS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 162. GLOBAL PSORIASIS DRUGS MARKET SIZE, BY INVERSE PSORIASIS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 163. GLOBAL PSORIASIS DRUGS MARKET SIZE, BY INVERSE PSORIASIS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 164. GLOBAL PSORIASIS DRUGS MARKET SIZE, BY INVERSE PSORIASIS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 165. GLOBAL PSORIASIS DRUGS MARKET SIZE, BY INVERSE PSORIASIS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 166. GLOBAL PSORIASIS DRUGS MARKET SIZE, BY INVERSE PSORIASIS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 167. GLOBAL PSORIASIS DRUGS MARKET SIZE, BY NAIL PSORIASIS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 168. GLOBAL PSORIASIS DRUGS MARKET SIZE, BY NAIL PSORIASIS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 169. GLOBAL PSORIASIS DRUGS MARKET SIZE, BY NAIL PSORIASIS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 170. GLOBAL PSORIASIS DRUGS MARKET SIZE, BY NAIL PSORIASIS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 171. GLOBAL PSORIASIS DRUGS MARKET SIZE, BY NAIL PSORIASIS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 172. GLOBAL PSORIASIS DRUGS MARKET SIZE, BY NAIL PSORIASIS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 173. GLOBAL PSORIASIS DRUGS MARKET SIZE, BY PLAQUE PSORIASIS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 174. GLOBAL PSORIASIS DRUGS MARKET SIZE, BY PLAQUE PSORIASIS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 175. GLOBAL PSORIASIS DRUGS MARKET SIZE, BY PLAQUE PSORIASIS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 176. GLOBAL PSORIASIS DRUGS MARKET SIZE, BY PLAQUE PSORIASIS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 177. GLOBAL PSORIASIS DRUGS MARKET SIZE, BY PLAQUE PSORIASIS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 178. GLOBAL PSORIASIS DRUGS MARKET SIZE, BY PLAQUE PSORIASIS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 179. GLOBAL PSORIASIS DRUGS MARKET SIZE, BY PUSTULAR PSORIASIS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 180. GLOBAL PSORIASIS DRUGS MARKET SIZE, BY PUSTULAR PSORIASIS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 181. GLOBAL PSORIASIS DRUGS MARKET SIZE, BY PUSTULAR PSORIASIS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 182. GLOBAL PSORIASIS DRUGS MARKET SIZE, BY PUSTULAR PSORIASIS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 183. GLOBAL PSORIASIS DRUGS MARKET SIZE, BY PUSTULAR PSORIASIS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 184. GLOBAL PSORIASIS DRUGS MARKET SIZE, BY PUSTULAR PSORIASIS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 185. GLOBAL PSORIASIS DRUGS MARKET SIZE, BY SCALP PSORIASIS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 186. GLOBAL PSORIASIS DRUGS MARKET SIZE, BY SCALP PSORIASIS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 187. GLOBAL PSORIASIS DRUGS MARKET SIZE, BY SCALP PSORIASIS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 188. GLOBAL PSORIASIS DRUGS MARKET SIZE, BY SCALP PSORIASIS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 189. GLOBAL PSORIASIS DRUGS MARKET SIZE, BY SCALP PSORIASIS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 190. GLOBAL PSORIASIS DRUGS MARKET SIZE, BY SCALP PSORIASIS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 191. GLOBAL PSORIASIS DRUGS MARKET SIZE, BY PATIENT TYPE, 2018-2024 (USD MILLION)
  • TABLE 192. GLOBAL PSORIASIS DRUGS MARKET SIZE, BY PATIENT TYPE, 2025-2032 (USD MILLION)
  • TABLE 193. GLOBAL PSORIASIS DRUGS MARKET SIZE, BY ADULTS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 194. GLOBAL PSORIASIS DRUGS MARKET SIZE, BY ADULTS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 195. GLOBAL PSORIASIS DRUGS MARKET SIZE, BY ADULTS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 196. GLOBAL PSORIASIS DRUGS MARKET SIZE, BY ADULTS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 197. GLOBAL PSORIASIS DRUGS MARKET SIZE, BY ADULTS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 198. GLOBAL PSORIASIS DRUGS MARKET SIZE, BY ADULTS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 199. GLOBAL PSORIASIS DRUGS MARKET SIZE, BY GERIATRIC, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 200. GLOBAL PSORIASIS DRUGS MARKET SIZE, BY GERIATRIC, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 201. GLOBAL PSORIASIS DRUGS MARKET SIZE, BY GERIATRIC, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 202. GLOBAL PSORIASIS DRUGS MARKET SIZE, BY GERIATRIC, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 203. GLOBAL PSORIASIS DRUGS MARKET SIZE, BY GERIATRIC, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 204. GLOBAL PSORIASIS DRUGS MARKET SIZE, BY GERIATRIC, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 205. GLOBAL PSORIASIS DRUGS MARKET SIZE, BY PEDIATRIC, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 206. GLOBAL PSORIASIS DRUGS MARKET SIZE, BY PEDIATRIC, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 207. GLOBAL PSORIASIS DRUGS MARKET SIZE, BY PEDIATRIC, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 208. GLOBAL PSORIASIS DRUGS MARKET SIZE, BY PEDIATRIC, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 209. GLOBAL PSORIASIS DRUGS MARKET SIZE, BY PEDIATRIC, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 210. GLOBAL PSORIASIS DRUGS MARKET SIZE, BY PEDIATRIC, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 211. GLOBAL PSORIASIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 212. GLOBAL PSORIASIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 213. GLOBAL PSORIASIS DRUGS MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 214. GLOBAL PSORIASIS DRUGS MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 215. GLOBAL PSORIASIS DRUGS MARKET SIZE, BY HOSPITAL PHARMACIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 216. GLOBAL PSORIASIS DRUGS MARKET SIZE, BY HOSPITAL PHARMACIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 217. GLOBAL PSORIASIS DRUGS MARKET SIZE, BY HOSPITAL PHARMACIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 218. GLOBAL PSORIASIS DRUGS MARKET SIZE, BY HOSPITAL PHARMACIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 219. GLOBAL PSORIASIS DRUGS MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 220. GLOBAL PSORIASIS DRUGS MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 221. GLOBAL PSORIASIS DRUGS MARKET SIZE, BY ONLINE PHARMACIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 222. GLOBAL PSORIASIS DRUGS MARKET SIZE, BY ONLINE PHARMACIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 223. GLOBAL PSORIASIS DRUGS MARKET SIZE, BY ONLINE PHARMACIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 224. GLOBAL PSORIASIS DRUGS MARKET SIZE, BY ONLINE PHARMACIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 225. GLOBAL PSORIASIS DRUGS MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 226. GLOBAL PSORIASIS DRUGS MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 227. GLOBAL PSORIASIS DRUGS MARKET SIZE, BY RETAIL PHARMACIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 228. GLOBAL PSORIASIS DRUGS MARKET SIZE, BY RETAIL PHARMACIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 229. GLOBAL PSORIASIS DRUGS MARKET SIZE, BY RETAIL PHARMACIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 230. GLOBAL PSORIASIS DRUGS MARKET SIZE, BY RETAIL PHARMACIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 231. GLOBAL PSORIASIS DRUGS MARKET SIZE, BY SPECIALTY PHARMACIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 232. GLOBAL PSORIASIS DRUGS MARKET SIZE, BY SPECIALTY PHARMACIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 233. GLOBAL PSORIASIS DRUGS MARKET SIZE, BY SPECIALTY PHARMACIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 234. GLOBAL PSORIASIS DRUGS MARKET SIZE, BY SPECIALTY PHARMACIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 235. GLOBAL PSORIASIS DRUGS MARKET SIZE, BY SPECIALTY PHARMACIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 236. GLOBAL PSORIASIS DRUGS MARKET SIZE, BY SPECIALTY PHARMACIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 237. GLOBAL PSORIASIS DRUGS MARKET SIZE, BY TREATMENT SETTING, 2018-2024 (USD MILLION)
  • TABLE 238. GLOBAL PSORIASIS DRUGS MARKET SIZE, BY TREATMENT SETTING, 2025-2032 (USD MILLION)
  • TABLE 239. GLOBAL PSORIASIS DRUGS MARKET SIZE, BY HOME-BASED TREATMENT, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 240. GLOBAL PSORIASIS DRUGS MARKET SIZE, BY HOME-BASED TREATMENT, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 241. GLOBAL PSORIASIS DRUGS MARKET SIZE, BY HOME-BASED TREATMENT, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 242. GLOBAL PSORIASIS DRUGS MARKET SIZE, BY HOME-BASED TREATMENT, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 243. GLOBAL PSORIASIS DRUGS MARKET SIZE, BY HOME-BASED TREATMENT, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 244. GLOBAL PSORIASIS DRUGS MARKET SIZE, BY HOME-BASED TREATMENT, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 245. GLOBAL PSORIASIS DRUGS MARKET SIZE, BY HOSPITAL-BASED CARE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 246. GLOBAL PSORIASIS DRUGS MARKET SIZE, BY HOSPITAL-BASED CARE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 247. GLOBAL PSORIASIS DRUGS MARKET SIZE, BY HOSPITAL-BASED CARE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 248. GLOBAL PSORIASIS DRUGS MARKET SIZE, BY HOSPITAL-BASED CARE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 249. GLOBAL PSORIASIS DRUGS MARKET SIZE, BY HOSPITAL-BASED CARE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 250. GLOBAL PSORIASIS DRUGS MARKET SIZE, BY HOSPITAL-BASED CARE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 251. GLOBAL PSORIASIS DRUGS MARKET SIZE, BY SPECIALTY DERMATOLOGY CLINICS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 252. GLOBAL PSORIASIS DRUGS MARKET SIZE, BY SPECIALTY DERMATOLOGY CLINICS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 253. GLOBAL PSORIASIS DRUGS MARKET SIZE, BY SPECIALTY DERMATOLOGY CLINICS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 254. GLOBAL PSORIASIS DRUGS MARKET SIZE, BY SPECIALTY DERMATOLOGY CLINICS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 255. GLOBAL PSORIASIS DRUGS MARKET SIZE, BY SPECIALTY DERMATOLOGY CLINICS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 256. GLOBAL PSORIASIS DRUGS MARKET SIZE, BY SPECIALTY DERMATOLOGY CLINICS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 257. GLOBAL PSORIASIS DRUGS MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 258. GLOBAL PSORIASIS DRUGS MARKET SIZE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 259. AMERICAS PSORIASIS DRUGS MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
  • TABLE 260. AMERICAS PSORIASIS DRUGS MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
  • TABLE 261. AMERICAS PSORIASIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
  • TABLE 262. AMERICAS PSORIASIS DRUGS MARKET SIZE, BY DRUG CLASS, 2025-2032 (USD MILLION)
  • TABLE 263. AMERICAS PSORIASIS DRUGS MARKET SIZE, BY BIOLOGICS, 2018-2024 (USD MILLION)
  • TABLE 264. AMERICAS PSORIASIS DRUGS MARKET SIZE, BY BIOLOGICS, 2025-2032 (USD MILLION)
  • TABLE 265. AMERICAS PSORIASIS DRUGS MARKET SIZE, BY SMALL MOLECULES, 2018-2024 (USD MILLION)
  • TABLE 266. AMERICAS PSORIASIS DRUGS MARKET SIZE, BY SMALL MOLECULES, 2025-2032 (USD MILLION)
  • TABLE 267. AMERICAS PSORIASIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 268. AMERICAS PSORIASIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 269. AMERICAS PSORIASIS DRUGS MARKET SIZE, BY INJECTABLE, 2018-2024 (USD MILLION)
  • TABLE 270. AMERICAS PSORIASIS DRUGS MARKET SIZE, BY INJECTABLE, 2025-2032 (USD MILLION)
  • TABLE 271. AMERICAS PSORIASIS DRUGS MARKET SIZE, BY ORAL, 2018-2024 (USD MILLION)
  • TABLE 272. AMERICAS PSORIASIS DRUGS MARKET SIZE, BY ORAL, 2025-2032 (USD MILLION)
  • TABLE 273. AMERICAS PSORIASIS DRUGS MARKET SIZE, BY TOPICAL, 2018-2024 (USD MILLION)
  • TABLE 274. AMERICAS PSORIASIS DRUGS MARKET SIZE, BY TOPICAL, 2025-2032 (USD MILLION)
  • TABLE 275. AMERICAS PSORIASIS DRUGS MARKET SIZE, BY PATIENT SEVERITY, 2018-2024 (USD MILLION)
  • TABLE 276. AMERICAS PSORIASIS DRUGS MARKET SIZE, BY PATIENT SEVERITY, 2025-2032 (USD MILLION)
  • TABLE 277. AMERICAS PSORIASIS DRUGS MARKET SIZE, BY PSORIASIS TYPE, 2018-2024 (USD MILLION)
  • TABLE 278. AMERICAS PSORIASIS DRUGS MARKET SIZE, BY PSORIASIS TYPE, 2025-2032 (USD MILLION)
  • TABLE 279. AMERICAS PSORIASIS DRUGS MARKET SIZE, BY PATIENT TYPE, 2018-2024 (USD MILLION)
  • TABLE 280. AMERICAS PSORIASIS DRUGS MARKET SIZE, BY PATIENT TYPE, 2025-2032 (USD MILLION)
  • TABLE 281. AMERICAS PSORIASIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 282. AMERICAS PSORIASIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 283. AMERICAS PSORIASIS DRUGS MARKET SIZE, BY TREATMENT SETTING, 2018-2024 (USD MILLION)
  • TABLE 284. AMERICAS PSORIASIS DRUGS MARKET SIZE, BY TREATMENT SETTING, 2025-2032 (USD MILLION)
  • TABLE 285. NORTH AMERICA PSORIASIS DRUGS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 286. NORTH AMERICA PSORIASIS DRUGS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 287. NORTH AMERICA PSORIASIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
  • TABLE 288. NORTH AMERICA PSORIASIS DRUGS MARKET SIZE, BY DRUG CLASS, 2025-2032 (USD MILLION)
  • TABLE 289. NORTH AMERICA PSORIASIS DRUGS MARKET SIZE, BY BIOLOGICS, 2018-2024 (USD MILLION)
  • TABLE 290. NORTH AMERICA PSORIASIS DRUGS MARKET SIZE, BY BIOLOGICS, 2025-2032 (USD MILLION)
  • TABLE 291. NORTH AMERICA PSORIASIS DRUGS MARKET SIZE, BY SMALL MOLECULES, 2018-2024 (USD MILLION)
  • TABLE 292. NORTH AMERICA PSORIASIS DRUGS MARKET SIZE, BY SMALL MOLECULES, 2025-2032 (USD MILLION)
  • TABLE 293. NORTH AMERICA PSORIASIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 294. NORTH AMERICA PSORIASIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 295. NORTH AMERICA PSORIASIS DRUGS MARKET SIZE, BY INJECTABLE, 2018-2024 (USD MILLION)
  • TABLE 296. NORTH AMERICA PSORIASIS DRUGS MARKET SIZE, BY INJECTABLE, 2025-2032 (USD MILLION)
  • TABLE 297. NORTH AMERICA PSORIASIS DRUGS MARKET SIZE, BY ORAL, 2018-2024 (USD MILLION)
  • TABLE 298. NORTH AMERICA PSORIASIS DRUGS MARKET SIZE, BY ORAL, 2025-2032 (USD MILLION)
  • TABLE 299. NORTH AMERICA PSORIASIS DRUGS MARKET SIZE, BY TOPICAL, 2018-2024 (USD MILLION)
  • TABLE 300. NORTH AMERICA PSORIASIS DRUGS MARKET SIZE, BY TOPICAL, 2025-2032 (USD MILLION)
  • TABLE 301. NORTH AMERICA PSORIASIS DRUGS MARKET SIZE, BY PATIENT SEVERITY, 2018-2024 (USD MILLION)
  • TABLE 302. NORTH AMERICA PSORIASIS DRUGS MARKET SIZE, BY PATIENT SEVERITY, 2025-2032 (USD MILLION)
  • TABLE 303. NORTH AMERICA PSORIASIS DRUGS MARKET SIZE, BY PSORIASIS TYPE, 2018-2024 (USD MILLION)
  • TABLE 304. NORTH AMERICA PSORIASIS DRUGS MARKET SIZE, BY PSORIASIS TYPE, 2025-2032 (USD MILLION)
  • TABLE 305. NORTH AMERICA PSORIASIS DRUGS MARKET SIZE, BY PATIENT TYPE, 2018-2024 (USD MILLION)
  • TABLE 306. NORTH AMERICA PSORIASIS DRUGS MARKET SIZE, BY PATIENT TYPE, 2025-2032 (USD MILLION)
  • TABLE 307. NORTH AMERICA PSORIASIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 308. NORTH AMERICA PSORIASIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 309. NORTH AMERICA PSORIASIS DRUGS MARKET SIZE, BY TREATMENT SETTING, 2018-2024 (USD MILLION)
  • TABLE 310. NORTH AMERICA PSORIASIS DRUGS MARKET SIZE, BY TREATMENT SETTING, 2025-2032 (USD MILLION)
  • TABLE 311. LATIN AMERICA PSORIASIS DRUGS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 312. LATIN AMERICA PSORIASIS DRUGS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 313. LATIN AMERICA PSORIASIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
  • TABLE 314. LATIN AMERICA PSORIASIS DRUGS MARKET SIZE, BY DRUG CLASS, 2025-2032 (USD MILLION)
  • TABLE 315. LATIN AMERICA PSORIASIS DRUGS MARKET SIZE, BY BIOLOGICS, 2018-2024 (USD MILLION)
  • TABLE 316. LATIN AMERICA PSORIASIS DRUGS MARKET SIZE, BY BIOLOGICS, 2025-2032 (USD MILLION)
  • TABLE 317. LATIN AMERICA PSORIASIS DRUGS MARKET SIZE, BY SMALL MOLECULES, 2018-2024 (USD MILLION)
  • TABLE 318. LATIN AMERICA PSORIASIS DRUGS MARKET SIZE, BY SMALL MOLECULES, 2025-2032 (USD MILLION)
  • TABLE 319. LATIN AMERICA PSORIASIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 320. LATIN AMERICA PSORIASIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 321. LATIN AMERICA PSORIASIS DRUGS MARKET SIZE, BY INJECTABLE, 2018-2024 (USD MILLION)
  • TABLE 322. LATIN AMERICA PSORIASIS DRUGS MARKET SIZE, BY INJECTABLE, 2025-2032 (USD MILLION)
  • TABLE 323. LATIN AMERICA PSORIASIS DRUGS MARKET SIZE, BY ORAL, 2018-2024 (USD MILLION)
  • TABLE 324. LATIN AMERICA PSORIASIS DRUGS MARKET SIZE, BY ORAL, 2025-2032 (USD MILLION)
  • TABLE 325. LATIN AMERICA PSORIASIS DRUGS MARKET SIZE, BY TOPICAL, 2018-2024 (USD MILLION)
  • TABLE 326. LATIN AMERICA PSORIASIS DRUGS MARKET SIZE, BY TOPICAL, 2025-2032 (USD MILLION)
  • TABLE 327. LATIN AMERICA PSORIASIS DRUGS MARKET SIZE, BY PATIENT SEVERITY, 2018-2024 (USD MILLION)
  • TABLE 328. LATIN AMERICA PSORIASIS DRUGS MARKET SIZE, BY PATIENT SEVERITY, 2025-2032 (USD MILLION)
  • TABLE 329. LATIN AMERICA PSORIASIS DRUGS MARKET SIZE, BY PSORIASIS TYPE, 2018-2024 (USD MILLION)
  • TABLE 330. LATIN AMERICA PSORIASIS DRUGS MARKET SIZE, BY PSORIASIS TYPE, 2025-2032 (USD MILLION)
  • TABLE 331. LATIN AMERICA PSORIASIS DRUGS MARKET SIZE, BY PATIENT TYPE, 2018-2024 (USD MILLION)
  • TABLE 332. LATIN AMERICA PSORIASIS DRUGS MARKET SIZE, BY PATIENT TYPE, 2025-2032 (USD MILLION)
  • TABLE 333. LATIN AMERICA PSORIASIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 334. LATIN AMERICA PSORIASIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 335. LATIN AMERICA PSORIASIS DRUGS MARKET SIZE, BY TREATMENT SETTING, 2018-2024 (USD MILLION)
  • TABLE 336. LATIN AMERICA PSORIASIS DRUGS MARKET SIZE, BY TREATMENT SETTING, 2025-2032 (USD MILLION)
  • TABLE 337. EUROPE, MIDDLE EAST & AFRICA PSORIASIS DRUGS MARKET SIZE, BY SU